Zelos Pipeline

Zelos is developing an innovative portfolio of complementary bone disease therapies covering osteoporosis, fracture repair, multiple myeloma, stem cell transplantation and renal bone disease. A focus on bone and bone marrow diseases allows us to efficiently leverage our expertise to rapidly advance bone formation agents – specifically PTH analogs -  through development for each indication.

* Investigator initiated study
** Based on Phase 1 safety data from the ZT-031 Osteoporosis clinical trial, ZT-031 Fracture Repair and Renal Bone Disease trials will begin in Phase 2.